Understanding regional variation in medicare expenditures for initial episodes of prostate cancer care

Medical Care

Volumn 52, Issue 8, 2014, Pages 680-687

  Wang, Shi Yi ^a,b   Wang, Rong ^a,b   Yu, James B ^a,c   Ma, Xiaomei ^a,b   Xu, Xiao ^a,d   Kim, Simon P ^a,e   Soulos, Pamela R ^a   Saraf, Avantika ^b   Gross, Cary P ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c Departments of Therapeutic Radiology and Dermatology   (United States)

^d Obstetrics and Gynaecology   (United States)

^e Section of Urology   (United States)

Author keywords

bundled payment; expenditures; prostate cancer; radiotherapy; regional variation; treatment modalities

Indexed keywords

AGED; ARTICLE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; DIAGNOSTIC IMAGING; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE COST; HUMAN; INCOME; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICARE; PATIENT CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROTON THERAPY; STEREOTACTIC RADIOSURGERY; TUMOR BIOPSY;

AGE FACTORS; AGED; AGED, 80 AND OVER; HEALTH EXPENDITURES; HUMANS; MALE; MEDICARE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RESIDENCE CHARACTERISTICS; SEER PROGRAM; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 84904467290     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0000000000000158     Document Type: Article

References (46)

1. Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103:117-128.
2. Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. JCO. 2011;29:1517-1524.
3. Elliott SP, Jarosek SL, Virnig BA. Changes Across Time and Geography in the Use of Prostate Radiation Technologies For Newly Diagnosed Older Cancer Patients: 2006-2008: Data Points #16. Rockville, MD: Data Points Publication Series; 2011.
4. Yu JB, Soulos PR, Herrin J, et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst. 2013;105:25-32.
5. Cantlupe J. Bundled payments come to cancer care. HealthLeaders Media. March 11, 2013. Available at: http://www.healthleadersmedia. com/page-2/COM-289965/Bundled-Payments-Come-to-Cancer-Care. Accessed September 30, 2013.
6. Butcher L. ONLINE FIRST: bundled payments come to oncology. Oncology Times. November 1, 2011. Available at: http://journals. lww.com/oncology-times/ blog/onlinefirst/pages/post.aspx?PostID = 318. Accessed September 30, 2013.
7. Centers for Medicare and Medicaid Services. Bundled Payments for Care Improvement (BPCI) Initiative. 2013. Available at: http://innovation.cms.gov/ initiatives/bundled-payments/index.html. Accessed September 30, 2013.
8. American Medical Association. Evaluating and negotiating emerging payment options. 2012. Available at: http://www.ama-assn.org/resources/doc/psa/payment- options.pdf#page = 87. Accessed September 30, 2013.
9. Altman SH. The lessons of Medicares prospective payment system show that the bundled payment program faces challenges. Health Aff (Millwood). 2012;31:1923-1930.
10. Epstein AM. Geographic variation in Medicare spending. N Engl J Med. 2010;363:85-86.
11. Sutherland JM, Fisher ES, Skinner JS. Getting past denial-The high cost of health care in the United States. N Engl J Med. 2009;361: 1227-1230.
12. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302: 1202-1209.
13. Krupski TL, Kwan L, Afifi AA, et al. Geographic and socioeconomic variation in the treatment of prostate cancer. JCO. 2005;23:7881-7888.
14. Spencer BA, Fung CH, Wang M, et al. Geographic variation across veterans affairs medical centers in the treatment of early stage prostate cancer. J Urol. 2004;172(pt 1):2362-2365.
15. Harlan L, Brawley O, Pommerenke F, et al. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. JCO. 1995;13:93-100.
16. Hamilton AS, Wu XC, Lipscomb J, et al. Regional, provider, and economic factors associated with the choice of active surveillance in the treatment of men with localized prostate cancer. J Natl Cancer Inst Monogr. 2012;45:213-220.
17. Nambudiri VE, Landrum MB, Lamont EB, et al. Understanding variation in primary prostate cancer treatment within the Veterans Health Administration. Urology. 2012;79:537-545.
18. Wilt TJ, Cowper DC, Gammack JK, et al. An evaluation of radical prostatectomy at Veterans Affairs Medical Centers: time trends and geographic variation in utilization and outcomes. Med Care. 1999;37:1046-1056.
19. Lai S, Lai H, Krongrad A, et al. Radical prostatectomy: geographic and demographic variation. Urology. 2000;56:108-115.
20. Lai S, Lai H, Lamm S, et al. Radiation therapy in non-surgically-treated nonmetastatic prostate cancer: geographic and demographic variation. Urology. 2001;57:510-517.
21. Makarov DV, Loeb S, Landman AB, et al. Regional variation in total cost per radical prostatectomy in the healthcare cost and utilization project nationwide inpatient sample database. J Urol. 2010;183:1504-1509.
22. Williams SB, Gu X, Lipsitz SR, et al. Utilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer. 2011;117:4846-4854.
23. Barlow WE. Overview of methods to estimate the medical costs of cancer. Medical Care. 2009;47(suppl 1):S33-S36.
24. Anderson G, Horvath J. The growing burden of chronic disease in America. Public Health Rep. 2004;119:263-270.
25. Newhouse JP, Garber AM. Geographic variation in Medicare services. N Engl J Med. 2013;368:1465-1468.
26. Dartmouth Medical School. Center for the Evaluative Clinical Sciences. The Dartmouth Atlas of Health Care. Chicago: American Hospital Publishing; 1996.
27. The Dartmouth Atlas of Health Care: crosswalks, ZIP code crosswalks 1995-2010. 2011. Available at: http://www.dartmouthatlas.org/tools/downloads. aspx. Accessed June 9, 2013.
28. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36:8-27.
29. Warren JL, Yabroff KR, Meekins A, et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008;100: 888-897.
30. Market basket data [database online]. Baltimore, MD: Centers for Medicare & Medicaid Services; 2013. Available at: http://www.cms.gov/Research- Statistics-Data-and-Systems/Statistics-Trendsand-Reports/ MedicareProgramRatesStats/MarketBasketData.html. Accessed June 9, 2013.
31. Centers for Medicare and Medicaid Services. PFS Relative Value Files, 2013 http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ PhysicianFeeSched/PFS-Relative-Value-Files.html. Accessed February 21, 2013.
32. Centers for Medicare and Medicaid Services. Wage Index Files. Baltimore, MD; 2013. http://www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/ AcuteInpatientPPS/Wage-Index-Files.htm. Accessed February 21, 2013.
33. Dixon WJ. Trimming and winsorization: a review. Statistical Papers. 1974;15:157-170.
34. Adams JL, Mehrotra A, Thomas JW, et al. Physician cost profiling: reliability and risk of misclassification.N Engl JMed. 2010;362:1014-1021.
35. Jha AK, Orav EJ, Dobson A, et al. Measuring efficiency: the association of hospital costs and quality of care. Health Aff (Millwood). 2009;28:897-906.
36. Liu L, Strawderman RL, Cowen ME, et al. A flexible two-part random effects model for correlated medical costs. J Health Econ. 2010;29: 110-123.
37. van Walraven C, Austin PC, Jennings A, et al. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Medical Care. 2009;47:626-633.
38. Schnipper LE, Smith TJ, Raghavan D, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. JCO. 2012;30:1715-1724.
39. Ma X, Wang R, Long JB, et al. The cost implications of prostate cancer screening in the Medicare population. Cancer. 2014;120:96-102.
40. Keegan KA, DallEra MA, Durbin-Johnson B, et al. Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. Cancer. 2012;118:3512-3518.
41. Hummel S, Simpson EL, Hemingway P, et al. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technol Assess. 2010;14: 1-108. iii-iv.
42. Jacobs BL, Zhang Y, Schroeck FR, et al. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA. 2013;309:2587-2595.
43. American Society for Radiation Oncology. ASTRO releases list of five radiation oncology treatments to question as part of national choosing wisely campaign [news release]. September 23, 2013. Available at: https://www.astro. org/uploadedFiles/Main-Site/News-and-Media/News-Releases/2013/ Choosing-Wisely-PR-FINAL-091713.pdf. Accessed September 30, 2013.
44. Reschovsky JD, Hadley J, Romano PS. Geographic variation in fee-forservice Medicare beneficiaries medical costs is largely explained by disease burden. Med Care Res Rev. 2013;70:542-563.
45. Bekelman JE, Suneja G, Guzzo T, et al. Effect of practice integration between urologists and radiation oncologists on prostate cancer treatment patterns. J Urol. 2013;190:97-101.
46. Jacobson M, Earle CC, Newhouse JP. Geographic variation in physicians responses to a reimbursement change. N Engl J Med. 2011; 365:2049-2052.